-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師總結如下:葛蘭素史克(GSK)公佈了2026年第一季業績,銷售額年增2%(固定匯率下為5%),超出預期。其中,特藥業務表現特別突出(年成長10%或固定匯率下為14%),特別是腫瘤藥物,Jemperli和Ojjaara的銷量強勁成長。疫苗業務也實現了4%的固定匯率成長,這主要得益於Shingrix創紀錄的銷售額。核心每股盈餘(EPS)成長4%(固定匯率下為9%),達到0.465英鎊,高於市場普遍預期的0.44英鎊。這主要得益於有利的產品組合和成本控制,使得核心營業利潤率提升了1.0個百分點(固定匯率下為1.8個百分點)。鑑於業績超出預期且利潤率有所提升,我們對第一季業績更新持正面態度,但我們也注意到匯率波動可能帶來的不利影響。葛蘭素史克重申了2026年業績指引,預期銷售額將成長3%-5%,核心營業利潤(固定匯率)成長7%-9%。儘管這項預期較2025年成長放緩,但與賽諾菲和羅氏等多家同業公司的預期基本一致。我們預計,關鍵的專科藥品將支撐營收成長,葛蘭素史克的目標是到2031年,該業務板塊的銷售額佔比超過50%(2026年第一季:42%)。我們認為,近期的收購將為公司成長和藥物研發管線注入強勁動力。
Related Articles
Fiera Capital Announcing Return of Maxime Menard As Global President and CEO
HD Hyundai Energy Solutions Turns to Profit in Q1
HD Hyundai Energy Solutions (KRX:322000) posted first-quarter net income of 22.3 billion won, rebounding from a net loss of 1.08 billion won a year earlier, according to a Wednesday filing with the Korea Exchange.The South Korean solar energy equipment supplier's sales jumped 88% year over year to 159.9 billion won from 85.3 billion won.Shares of HD Hyundai Energy Solutions jumped more than 9% at market close.
Shandong Sunpaper's Attributable Profit Jumps 2% in Q1
Shandong Sunpaper's (SHE:002078) attributable profit rose 2.3% to 906.4 million yuan in the first quarter from 886.1 million yuan in the year-ago period, according to a Wednesday filing with the Shenzhen bourse.Earnings per share at the paper manufacturer increased to 0.3243 yuan from 0.3171 yuan in the prior-year period.Operating revenue grew 1.9% year over year to 10.1 billion yuan from 9.90 billion yuan.